Arizona philanthropist Catherine (Bracken) Ivy keeps her focus on those diagnosed with brain cancer

17-07-2012

The Ben & Catherine Ivy Foundation has awarded $10 million in grants for two brain cancer research projects at the Translational Genomics Research Institute (TGen).One $five-million-project is titled "Outliers in Glioblastoma Outcome: Moving the curve forward." This five-year investigation ...

more

21-06-2012

e-Therapeutics plc announces the start of the first clinical trial evaluating its compound ETS2101 as a treatment for cancer. The phase I trial is enrolling patients with primary brain cancer (glioma) or cancer that has spread to the brain from other sites. Led by Professor Santosh Kesari, ...

more

30-03-2012

Treating invasive brain tumors with a combination of chemotherapy and radiation has improved clinical outcomes, but few patients survive longer than two years after diagnosis. The effectiveness of the treatment is limited by the tumor's aggressive invasion of healthy brain tissue, which ...

more

16-09-2011

Cornell researchers may have solved a 100-year puzzle: How to safely open and close the blood-brain barrier so that therapies to treat Alzheimer's disease, multiple sclerosis and cancers of the central nervous system might effectively be delivered.The researchers have identified that ...

more

Two new studies now ongoing: phase Ib/II in patients with aggressive brain tumour and phase Ib in primary liver cancer

17-05-2011

BioInvent International AB and co-development partner ThromboGenics NV announced that their partner Roche has dosed the first patient in a phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334). The trial is in patients with glioblastoma multiforme, the most common and ...

more

04-04-2011

to-BBB is getting ready to point its brain-targeting platform to patients with brain cancer. The Dutch Ministry of Economic Affairs, Agriculture and Innovation (Agentschap NL) supports to-BBB in this challenge by granting an “Innovation Credit”, covering 35% of the costs needed for clinical ...

more

21-01-2011

Scientists around the world have been hot on the trail of a genetic mutation closely associated with some brain cancers and leukemia since the mutation's discovery in 2008. The hunt is now yielding fruit. In of Cancer Cell, researchers reveal how the mutation contributes to cancer development ...

more

Focus on molecular diagnostic testing for personalized medicine in oncology

20-10-2010

MDxHealth, formerly known as OncoMethylome Sciences, announced further details regarding its revised business strategy. For the past several months, MDxHealth’s management has worked very closely with the Board of Directors to define a strategic path to accelerate growth and monetization of ...

more

25-08-2010

to-BBB announced that the Food and Drug Administration (FDA) has granted orphan drug designation for to-BBB’s brain cancer lead product 2B3-101. As a proprietary brain-targeted version of the marketed product Caelyx®/Doxil® (PEG-liposomal doxorubicin), 2B3-101 uses glutathione (GSH) to ...

more

04-08-2010

Tiny particles of iron oxide could become tools for simultaneous tumor imaging and treatment, because of their magnetic properties and toxic effects against brain cancer cells. In mice, researchers from Emory University School of Medicine have demonstrated how these particles can deliver ...

more